Qian

LianBio Appoints Pascal Qian as General Manager of China

Retrieved on: 
Monday, August 2, 2021
Health, Biotechnology, Chemical compounds, Organic compounds, Aminopyridines, Thioethers, Chloroarenes, Specialty drugs, Protein kinase inhibitors, Palbociclib, Sunitinib, Axitinib, Crizotinib, Qian

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

Key Points: 
  • LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.
  • Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair.
  • He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.
  • Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China.

Xiaoling Qian Appointed to Board of Directors of Opera Limited

Retrieved on: 
Tuesday, June 8, 2021
Software, Operating systems, Web browsers, Opera, Xiaoling, Qian, Kunlun

OSLO, Norway, June 8, 2021 /PRNewswire/ -- Opera Limited (Nasdaq: OPRA) ("Opera"), one of the world's largest internet consumer brands with hundreds of millions of users worldwide, today announced that Ms. Xiaoling Qian has joined Opera's Board of Directors.

Key Points: 
  • OSLO, Norway, June 8, 2021 /PRNewswire/ -- Opera Limited (Nasdaq: OPRA) ("Opera"), one of the world's largest internet consumer brands with hundreds of millions of users worldwide, today announced that Ms. Xiaoling Qian has joined Opera's Board of Directors.
  • Xiaoling Qian is an executive of Kunlun (300418:CH), a Beijing based mobile gaming and Internet company that is Opera's largest shareholder.
  • Ms. Qian has taken a leading role in managing Kunlun's investment in Opera and has worked with our other board members and the Opera management team since 2016.
  • Ms. Qian will serve as a replacement for another Kunlun executive, Tian Jin, on the Opera board.